PET/CT Changes During Chemoimmunotherapy and Radiation Therapy in Patients With Stage IV Non-small Cell Lung Cancer
Conditions: Metastatic Lung Non-Small Cell Carcinoma; Recurrent Lung Non-Small Cell Carcinoma; Stage IV Lung Cancer AJCC v8; Stage IVA Lung Cancer AJCC v8; Stage IVB Lung Cancer AJCC v8 Interventions: Procedure: Positron Emission Tomography; Procedure: Computed Tomography; Drug: Chemotherapy; Biological: Immunotherapy; Radiation: Radiation Therapy Sponsors: University of Washington; National Cancer Institute (NCI) Recruiting
Viacheslav Soyfer1* and Benjamin W. Corn2 1Tel Aviv Medical Center, Tel Aviv University, Tel Aviv, Israel 2Shaare Zedek Medical Center, Hebrew University of Jerusalem, Jerusalem, Israel Outcomes for patients with locally-advanced Non Small Cell Lung Cancer (NSCLC) remain poor. In the context of definitive (as opposed to neoadjuvant) treatment, radiation oncologists have traditionally embraced dose escalation as a means to improve control of the primary tumor as well as draining nodal regions for this clinical problem. Yet we wonder: is it optimal—or even rational—to treat the primary and the medi...
This study was supported by the Shanghai Sailing Program [grant number 17YF1425200, 2017]; Chinese National Natural Science Funding [grant number 81702249, 2017]; Science and Technology Commission of Shanghai Municipality [grant number 17511103403, 2017]; The funder has no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. Conflict of Interest Statement The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. Acknowledgments We acknowledge the ex...
Recently, many combination therapies involving an immune checkpoint inhibitor targeting the programmed cell death-1 (PD-1)/programmed cell death-ligand 1 (PD-L1) pathway and another treatment option such as chemotherapy, radiation therapy, and various immunotherapy agents have been explored to improve the response rate and clinical outcomes in various solid tumors including non-small cell lung cancer (NSCLC) [1 –8]. Especially, combination therapy with an indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor and a PD-1/PD-L1 inhibitor is expected to be a novel and effective treatment option and is currently attracting a lot of attention.
Conclusions: This paper aims to alert for this rare and aggressive tumor, affecting mostly smoking male, which remains poorly explored. The better knowledge of PSC biology and molecular profile is critical for understanding the role of immunotherapy and targeted agents in this difficult to treat disease.